The Recall Desk

Hazard

Allergen Exposure recalls

168 recalls in our database tag this hazard, drawn from FDA, USDA FSIS, CPSC, and NHTSA source notices.

What the numbers show

Total
168
Critical
0
Severe
148
Most recent
2016-07-27

Of the 168 allergen exposure recalls we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 148 (88%) are Severe.

About this hazard tag

Hazard tags are short, machine-readable labels we attach to every recall to make cross-cutting queries possible — “all allergen exposure recalls regardless of agency”, “all listeria recalls in California”, “all airbag recalls in 2025”. The tags are extracted from each recall’s source text during the LLM rewrite step and validated against a fixed schema.

A recall can carry multiple tags — a Listeria recall might also be tagged ready-to-eat and undeclared-allergen. Use the full-text search if you want to combine hazard tags with brand or category filters.

126–150 of 168

  • SevereFDA (Drugs)·D-523-2015·2015-04-29

    Attix Pharmaceuticals Recalls Aprepitant API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Aprepitant active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Aprepitant active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-811-2015·2015-04-29

    Attix Pharmaceuticals Recalls Naftifine HCl Due to Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Naftifine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Naftifine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-760-2015·2015-04-29

    Levosulpiride API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Levosulpiride active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Levosulpiride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-714-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydrocortisone Base Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of hydrocortisone base active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.

    Product
    Hydrocortisone base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-798-2015·2015-04-29

    Miltefosine API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Miltefosine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Miltefosine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-730-2015·2015-04-29

    Attix Pharmaceuticals Recalls Imatinib Mesylate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Imatinib Mesylate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Imatinib Mesylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-910-2015·2015-04-29

    Tacrolimus Monohydrate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Tacrolimus Monohydrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Tacrolimus Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-697-2015·2015-04-29

    Attix Pharmaceuticals Recalls Gatifloxacin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Gatifloxacin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Gatifloxacin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-712-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydrochlorothiazide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hydrochlorothiazide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Hydrochlorothiazide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-638-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dopamine HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Dopamine HCI active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Dopamine HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-698-2015·2015-04-29

    Gefitinib API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Gefitinib active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Gefitinib active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-948-2015·2015-04-29

    Valacyclovir HCl Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Valacyclovir HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Valacyclovir HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-766-2015·2015-04-29

    Attix Pharmaceuticals Recalls Lisinopril Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Lisinopril active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Lisinopril active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-820-2015·2015-04-29

    Attix Pharmaceuticals Recalls Norethindrone Acetate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Norethindrone Acetate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Norethindrone Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-639-2015·2015-04-29

    Attix Pharmaceuticals Recalls Doxapram HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Doxapram HCI Monohydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Doxapram HCI Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-534-2015·2015-04-29

    Baclofen API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Baclofen active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Baclofen active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-612-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dantrolene Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Dantrolene Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Dantrolene Sodium (Orange) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-923-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tetracaine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tetracaine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Tetracaine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-917-2015·2015-04-29

    Attix Pharmaceuticals Recalls Telaprevir API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Telaprevir active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Telaprevir active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-595-2015·2015-04-29

    Attix Pharmaceuticals Recalls Clomipramine HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Clomipramine HCI active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Clomipramine HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-824-2015·2015-04-29

    Attix Pharmaceuticals Recalls Omeprazole Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Omeprazole Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Omeprazole Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-708-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hyaluronic Acid Sodium Salt Injection Grade API

    Attix Pharmaceuticals is recalling Hyaluronic Acid Sodium Salt (Injection Grade) active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Hyaluronic Acid Sodium Salt (Injection Grade) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-927-2015·2015-04-29

    Attix Pharmaceuticals Recalls Thiotepa Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Thiotepa active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Thiotepa active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-767-2015·2015-04-29

    Attix Pharmaceuticals Recalls Lodenafil Carbonate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Lodenafil Carbonate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Lodenafil Carbonate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-679-2015·2015-04-29

    Flumazenil API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Flumazenil active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Flumazenil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide